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Varicella Vaccine Effectiveness 
in Preventing Community 
Transmission in the 2-Dose Era
Dana Perella, MPH, a Chengbin Wang, PhD, b Rachel Civen, MD, MPH, c Kendra Viner, PhD, MPH, a Karen 
Kuguru, MPA, c Irini Daskalaki, MD, a D. Scott Schmid, PhD, b Adriana S. Lopez, MHS, b Hung Fu Tseng, PhD, 
MPH, d E. Claire Newbern, PhD, MPH, a Laurene Mascola, MD, MPH, c Stephanie R. Bialek, MD, MPHb
abstractOBJECTIVES: We examined overall and incremental effectiveness of 2-dose varicella 
vaccination in preventing community transmission of varicella among children aged 4 to 
18 years in 2 active surveillance sites. One-dose varicella vaccine effectiveness (VE) was 
examined in those aged 1 to 18 years.
METHODS: From May 2009 through June 2011, varicella cases identified during active 
surveillance in Antelope Valley, CA and Philadelphia, PA were enrolled into a matched 
case–control study. Matched controls within 2 years of the patient’s age were selected from 
immunization registries. A standardized questionnaire was administered to participants’ 
parents, and varicella vaccination history was obtained from health care provider, 
immunization registry, or parent records. We used conditional logistic regression to 
estimate varicella VE against clinically diagnosed and laboratory-confirmed varicella.
RESULTS: A total of 125 clinically diagnosed varicella cases and 408 matched controls were 
enrolled. Twenty-nine cases were laboratory confirmed. One-dose VE (1-dose versus 
unvaccinated) was 75.6% (95% confidence interval [CI], 38.7%–90.3%) in preventing 
any clinically diagnosed varicella and 78.1% (95% CI, 12.7%–94.5%) against moderate or 
severe, clinically diagnosed disease (≥50 lesions). Among subjects aged ≥4 years, 2-dose 
VE (2-dose versus unvaccinated) was 93.6% (95% CI, 75.6%–98.3%) against any varicella 
and 97.9% (95% CI, 83.0%–99.7%) against moderate or severe varicella. Incremental 
effectiveness (2-dose versus 1-dose) was 87.5% against clinically diagnosed varicella and 
97.3% against laboratory-confirmed varicella. 
CONCLUSIONS: Two-dose varicella vaccination offered better protection against varicella from 
community transmission among school-aged children compared with 1-dose vaccination.
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WHAT’S KNOWN ON THIS SUBJECT: Declines in varicella 
incidence since 2006 and vaccine effectiveness estimates 
from outbreak investigations indicate that 2-dose 
varicella vaccination provides improved protection 
against varicella. Limited data exist on the performance 
of 2-dose varicella vaccination in preventing community 
transmission outside outbreak settings.
WHAT THIS STUDY ADDS: Two-dose varicella vaccination 
improved protection against community transmission of 
varicella among school-aged children in 2 geographically 
and demographically diverse areas compared with 1-dose 
vaccination. Our study provides more direct evidence on 
the protective effect of a 2-dose varicella vaccine regimen.
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Between 1995 and 2005, the 1-dose 
varicella vaccination program in 
the United States greatly reduced 
varicella incidence, hospitalizations, 
and deaths.1–4 However, between 
2001 and 2006, varicella outbreaks 
in school settings with high 1-dose 
vaccination coverage (>80% among 
students without varicella history) 
continued to be reported.5–11 Clinical 
trial data had demonstrated that the 
immune response produced 6 weeks 
after 2-dose varicella vaccination 
was 12 times higher than levels after 
1-dose vaccination, which translated 
into a threefold reduction in 
breakthrough varicella over a 10-year 
period.12 Therefore, in 2006 the 
Advisory Committee on Immunization 
Practices recommended 
implementation of a routine 2-dose 
varicella vaccination program for 
children aged 4 to 6 years.13
Declines in varicella incidence 
reported since 2006 along with 
varicella vaccine effectiveness 
(VE) estimates from a case–control 
study conducted as part of active 
surveillance of outbreaks in West 
Virginia indicate that the 2-dose 
regimen provides improved 
protection against varicella.14–18 
However, limited field data exist 
on the performance of a 2-dose 
varicella vaccination program in 
preventing community transmission 
other than in outbreak settings that 
may underestimate the true vaccine 
effectiveness.18, 19 A community-based 
case–control study in Connecticut 
found 2-dose varicella VE was 98.3%, 
but no 2-dose cases were identified 
in the study.20 As this study 
demonstrates, obtaining precise 2-dose 
varicella VE estimates is challenging 
because of the lower varicella 
incidence in the 2-dose era, particularly 
among recipients of both doses.
To evaluate the 2-dose varicella 
VE, we conducted a matched 
case–control study to examine 
the overall and incremental VE of 
the 2-dose varicella vaccination 
regimen in preventing varicella 
among school-aged children (4–18 
years) in 2 geographically and 
demographically diverse areas under 
active surveillance for varicella. 
Secondary study objectives were 
to estimate 1-dose VE among 
children aged 1 to 18 years during 
the 2-dose era and determine risk 
factors associated with breakthrough 
varicella among 2-dose recipients.
METHODS
Study Population and Setting
From May 2009 through June 
2011, investigators from Antelope 
Valley (AV) and West Philadelphia 
Varicella Active Surveillance Project 
(VASP) conducted this matched 
case–control study in collaboration 
with the Centers for Disease Control 
and Prevention (CDC). Institutional 
review boards at all 3 participating 
institutions approved the study 
protocol. The target populations for 
case and control subject recruitment 
were residents aged 1 to 18 years 
from AV and Philadelphia. AV spans 
~2200 square miles of northern Los 
Angeles County and has a population 
of >370 000 residents.21 Philadelphia 
is a large and densely populated 
metropolis with 1.5 million 
residents.22 During the study, the 
majority of AV residents <20 years 
of age were either Hispanic (51%) or 
non-Hispanic white (30%).21 Among 
those of same age in Philadelphia, 
48% were non-Hispanic black, 28% 
were non-Hispanic white, and only 
16% were Hispanic.22
Case Recruitment
In AV and Philadelphia, varicella 
cases were identified prospectively 
through population-based active 
surveillance methods. More than 300 
participating community-based sites 
(eg, schools, health care provider 
offices) in each surveillance area 
reported suspected varicella cases or 
informed project staff that no cases 
occurred at their facility biweekly.15, 
23 During the 2010 to 2011 academic 
year, active surveillance was 
expanded from West Philadelphia 
to include an additional 232 
schools that were located in other 
areas of Philadelphia. Eligible case 
subjects in Philadelphia were also 
identified through citywide passive 
surveillance. All case reports were 
investigated with the standardized 
VASP questionnaire.15, 23
After investigation, a case subject 
was defined as a person residing in 
AV or Philadelphia with no previous 
history of varicella and acute onset 
of a diffuse maculopapulovesicular 
rash or, for previously vaccinated 
people, modified maculopapular 
rash with few or no vesicles that 
a medical provider definitively 
diagnosed as varicella without any 
other apparent cause.15, 24 In May 
2009 through July 2010, enrollment 
was limited to children aged 5 to 14 
years with laboratory confirmation 
of varicella-zoster virus (VZV) by 
polymerase chain reaction (PCR) 
testing. During August 2010 through 
June 2011, enrollment was expanded 
to include people 1 to 18 years 
of age with laboratory or clinical 
diagnosis of varicella by a health care 
provider. Laboratory confirmation 
was expanded to include positive 
VZV-specific PCR, direct fluorescent 
antibody assay, or culture results.
Control Selection
Control subjects were selected from 
the Kaiser Permanente Southern 
California membership database 
and the Philadelphia Department of 
Public Health’s Kids Immunization 
Database/Tracking System 
registry in AV and Philadelphia, 
respectively. Kaiser Permanente 
Southern California, an integrated 
health care system, provides 
comprehensive health services 
to 30% of AV residents aged 1 to 
19 years; vaccine administration 
data for its members are stored in 
the Kaiser Immunization Tracking 
System and include information 
on vaccine doses administered by 
2
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providers inside and outside the 
Kaiser network or verified through 
school or provider records for 
vaccinations given before enrollment. 
Kaiser Permanente also was an active 
surveillance reporting site in AV. The 
Philadelphia Department of Public 
Health immunization registry has 
used health department birth records 
and vaccine administration reporting 
from health care providers to 
establish and maintain immunization 
records for all children aged ≤6 
years in Philadelphia since 1995. The 
registry expanded to include children 
aged ≤18 years in 2007.
For each varicella case identified 
that met study inclusion criteria, 
we selected potential controls using 
incidence density sampling by 
extracting age-matched (±2 years) 
records for all children from the pool 
of eligible controls aged 1 to 18 years 
who did not have a previous varicella 
history documented in historic 
surveillance data or immunization 
registry.25 A 2-year age range for 
controls was chosen, because the 
routine 2-dose varicella vaccination 
recommendation spans ages 4 to 6 
years.13 Moreover, because routine 
1-dose coverage reached higher 
levels (>80%), protection from 
1-dose varicella vaccination appears 
to remain consistent during the 
first few years after vaccination.13 
Between 5 and 60 potential control 
subjects were randomly selected 
from the corresponding control pool 
for each incident case. To be able to 
analyze VE among the age groups for 
which the first and second doses of 
varicella vaccine are recommended, 
controls selected for cases aged 1 
to 3 years had to be <4 years of age, 
and controls selected for cases ≥4 
years of age had to be ≥4 years of 
age. Study staff sent an invitation 
letter and contacted parents or 
guardians of eligible control subjects 
via telephone. The first 3 eligible 
respondents who consented to 
participate were the controls for each 
incident case. Recruited controls 
were eligible to be controls for 
subsequent incident cases, and if she 
or he developed varicella at a later 
time point, the subject was eligible 
for the study as a case subject.
Data Collection
Study staff obtained verbal consent 
and collected data from a parent or 
guardian of each subject by telephone 
by using a standard questionnaire. 
Given limited study resources, we 
did not recruit cases and controls 
with non-English-speaking parents 
or guardians who could not provide 
consent because of the language 
barrier. The questionnaires captured 
information on demographics, 
varicella vaccination history, recent 
VZV exposures, underlying medical 
conditions, and use of immune-
suppressing medications. The case 
questionnaire, which has been 
described previously, included 
additional disease-specific questions 
and standardized prompts to obtain 
the number of lesions.23 VASP staff 
scheduled home visits to collect 
lesion specimens from eligible cases 
reported before their rashes had 
resolved. The CDC National VZV 
Laboratory performed PCR testing26, 
27 on lesion specimens collected 
from suspected varicella cases. For 
a few cases, VZV-specific testing was 
conducted by hospital or commercial 
reference laboratories. Participating 
families received a $10–$20 gift 
card after completion of study-
related activities, and AV health care 
providers were offered a $20 gift 
card for every case reported with 
lesion specimens collected.
For case and control subjects, 
varicella vaccination administration 
dates were collected from the 
registries used for control selection, 
parental records, and the subject’s 
health care provider. Study staff 
made efforts to validate vaccination 
information for all subjects with the 
immunization registry or health care 
provider records. If a discrepancy 
existed between these 2 sources, 
the source with the most complete 
information (ie, highest number of 
doses) was used. We considered 
1-dose varicella vaccination to be 
valid when given 4 days before a 
child’s first birthday or later. Second-
dose varicella vaccination was 
considered valid when administered 
≥4 weeks after the first dose. The 
last dose also needed to be given 
>42 days before rash onset for cases 
(breakthrough varicella) or the 
matched incident case’s onset for 
controls. Those given doses within 42 
days were excluded.
Data Analysis
For our main analysis, we combined 
data from both sites, because 
varicella vaccine coverage and risk 
for breakthrough varicella have not 
differed between sociodemographic 
subgroups, 13, 28 and the directions 
of estimates from each site were 
similar. We used 2 case definitions 
for varicella: clinically diagnosed 
and laboratory confirmed. Varicella 
severity was categorized based on 
the number of lesions reported as 
mild (<50 lesions), moderate (50–500 
lesions), or severe (>500 lesions). 
The following VE estimates were 
calculated to examine protection 
against any varicella or moderate or 
severe disease alone (≥50 lesions): 
incremental 2-dose VE (2 doses 
versus 1 dose), overall 2-dose VE 
(2 doses versus unvaccinated), and 
overall 1-dose VE (1 dose versus 
unvaccinated). All VE estimates were 
calculated with Greenwood and Yule’s 
formula: VE = 1 − relative risk (RR).19 
In our study, RR refers to the risk 
of developing varicella among the 
subgroup with the higher number 
of varicella vaccine doses compared 
with the subgroup with fewer or no 
doses and was estimated with an 
odds ratio (OR) from conditional 
logistic regression to account for the 
matching variable (age). We were 
able to adjust for other potential 
confounders when examining VE 
against clinically diagnosed disease 
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using the combined site data. Changes 
in VE by time since vaccination (rash 
onset date minus the date of most 
recent varicella vaccination) were 
calculated via previously described 
methods.25 The distribution of 
categorical or continuous variables 
between cases and controls was 
examined with Mantel–Haenszel 
χ2 test, Fisher’s exact test, Mann–
Whitney U test, or Kruskal–Wallis test 
where appropriate. All analyses were 
conducted in SAS 9.3 (SAS Institute, 
Inc, Cary, NC).
RESULTS
Case and Control Subject 
Characteristics
A total of 125 clinically diagnosed 
varicella cases and 408 matched 
controls were enrolled. Of the 
44 (35.2%) cases that had lesion 
specimens tested for VZV, 29 were 
laboratory-confirmed cases (all PCR 
positive), 11 were PCR negative 
(median lesion collection day: 5 
[range: 2–21]), 2 had inadequate 
specimens, and 2 were culture 
negative. The median age of clinically 
diagnosed cases was 2.1 years 
among those aged <4 years and 
9.5 years among those aged ≥4 
years (Table 1). For each case, 2 to 
7 matched controls (median = 3) 
were recruited after we approached 
a median of 5 (range: 5–15) and 
29 (range: 5–60) eligible people in 
AV and Philadelphia, respectively. 
The distribution of demographic 
characteristics did not differ 
significantly between clinically 
diagnosed case and control subjects, 
except day care attendance among 
those aged ≥4 years (P = .03). Most 
controls aged ≥4 years from AV and 
Philadelphia had received ≥1 dose of 
varicella vaccine (98.8% vs 95.5%, 
P = .05), and the majority in each 
site had received 2 doses (78.5% 
vs 83.6%, P = .31). Although the 
proportion of vaccinated cases aged 
≥4 years from each site was similar 
(91% to 92%), the proportion of 
cases aged ≥4 years who were 2-dose 
recipients was slightly lower in AV 
than Philadelphia (41.1% vs 59.5%, 
P = .08).
Among clinically diagnosed cases 
≥4 years of age, rash severity 
and characteristics differed 
significantly by vaccination status, 
with the majority of breakthrough 
cases reporting mild and mostly 
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TABLE 1  Demographic and Vaccination Characteristics of Clinically Diagnosed Varicella Case and Control Subjects From Philadelphia, Pennsylvania and 
Antelope Valley, California, 2009–2011a
Aged 1–3 y Aged ≥4 y
Cases (n = 32), 
n (%)
Controls (n = 103), 
n (%)
P Cases (n = 93), 
n (%)
Controls (n = 305), 
n (%)
P
Median age 2.1 (1.0–3.9) 2.2 (1.1–3.9) .53 9.5 (4.0–18.9) 9.3 (4.1–18.9) .58
Surveillance site .68 .48
 Antelope Valley, CA 9 (28.1) 33 (32.0) 56 (60.2) 171 (56.1)
 Philadelphia, PA 23 (71.9) 70 (68.0) 37 (39. 8) 134 (43.9)
Vaccination status <.001 <.001
 Unvaccinated 9 (28.1) 4 (3.9) 8 (8.6) 8 (2.6)
 1-dose 22 (68.8) 98 (95.1) 40 (43.0) 50 (16.4)
 2-dose 1 (3.1) 1 (1.0) 45 (48.4) 247 (81.0)
Race .09 .43
 White 12 (37.5) 46 (44.7) 59 (63.4) 171 (56.1)
 African American 9 (28.1) 40 (38.8) 25 (26.9) 95 (31.1)
 Other 11 (34.4) 17 (16.5) 9 (9.7) 39 (12.8)
Ethnicity .18 .20
 Hispanic 14 (45.2) 33 (32.0) 40 (43.0) 109 (35.7)
 Non-Hispanic 17 (54.8) 70 (68.0) 53 (57.0) 196 (64.3)
Gender .41 .87
 Male 16 (50.0) 60 (58.3) 47 (50.5) 157 (51.5)
 Female 16 (50.0) 43 (41.7) 46 (49.5) 148 (48.5)
Born in United States >.999 >.999
 Yes 31 (100.0) 103 (100.0) 91 (97.8) 296 (97.0)
 No 0 (0.0) 0 (0.0) 2 (2.2) 9 (3.0)
Immunosuppressing condition >.999 >.999
 Yes 0 (0.0) 0 (0.0) 0 (0.0) 2 (0. 7)
 No 32 (100.0) 103 (100.0) 92 (100.0) 303 (99.3)
Asthma .99 .26
 Yes 6 (18.8) 19 (18.6) 19 (20.4) 47 (15.5)
 No 26 (81.3) 83 (81.4) 74 (79.6) 257 (84.5)
Attend day care .62 .03
 Yes 13 (40.6) 47 (45.6) 6 (4.5) 47 (15.4)
 No 19 (59.4) 56 (54.4) 87 (93.5) 258 (84.6)
a Missing and unknown responses excluded. Valid percentages presented.
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maculopapular rashes, whereas 
most unvaccinated cases had 50–500 
lesions that were mostly vesicular 
(Table 2). There was no severe 
varicella among 2-dose cases. Only 
2 cases had >500 lesions; both were 
otherwise healthy adolescents, of 
whom, 1 was a 1-dose recipient and 
the other unvaccinated. None of 
the cases were hospitalized due to 
varicella or developed complications 
of varicella. Among breakthrough 
cases aged ≥4 years, 2-dose cases 
were more likely to have rashes that 
resolved in <1 week (P = .01) and 
were less likely to have vesicular 
rashes (P = .01) than 1-dose cases. 
Presence and duration of fever did 
not differ significantly between 
breakthrough and unvaccinated 
cases.
Varicella Vaccine Effectiveness
Among all unvaccinated and 1-dose 
participants, the effectiveness 
of 1-dose of varicella vaccine 
compared with no vaccine was 
75.6% (95% confidence interval 
[CI], 38.7%–90.3%) against all 
clinically diagnosed varicella and 
78.1% (95% CI, 12.7%–94.5%) 
against moderate or severe disease 
(Table 3). The effectiveness of 2 
doses of varicella vaccine compared 
with no vaccine among subjects 
aged ≥4 years was 93.6% (95% CI, 
75.6%–98.3%) against all clinically 
diagnosed varicella and 97.9% (95% 
CI, 83.0%–99.7%) against moderate 
or severe varicella. The incremental 
effectiveness of 2-dose varicella 
vaccination compared with 1-dose 
among participants ≥4 years of age 
was 87.5% (95% CI, 74.9%–93.7%) 
in preventing any clinically diagnosed 
varicella and 94.1% (95% CI, 72.4%–
98.8%) in preventing moderate or 
severe clinically diagnosed disease.
VE estimates were higher but not 
significantly in AV than Philadelphia. 
Among subjects aged ≥4 years from 
AV, 2-dose VE and incremental VE 
against any clinically diagnosed 
varicella were 98.4% and 92.4%, 
respectively. In Philadelphia, 2-dose 
VE and incremental VE among 
subjects ≥4 years old were 92.7% 
and 79.8%, respectively. Two-
dose VE estimates did not differ 
significantly between sites (P = 
0.20); however, the small number of 
unvaccinated cases (≤5) and controls 
(≤6) may have led to unstable VE 
estimates by site.
Among the 26 laboratory-confirmed 
cases aged ≥4 years and their 
matched controls, 2-dose varicella VE 
was 95.9% (95% CI, 23.2%–99.8%), 
and incremental VE was 97.3% (95% 
CI, 88.9%–100%). Because data 
were sparse, we could not assess 
effectiveness of 1-dose of varicella 
vaccine against laboratory-confirmed 
varicella.
Risk Factors for Breakthrough 
Varicella Among 2-Dose Varicella 
Vaccine Recipients
Among 2-dose varicella vaccine 
recipients, there was no association 
between time since receiving dose 
2 and breakthrough varicella (P = 
.17; Table 4). However, those who 
received the second dose after 6 
years of age were 60% less likely 
to have breakthrough varicella 
than those who had received the 
second dose at an earlier age (P 
= .009). A longer time interval 
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TABLE 2  Varicella Disease Severity by Vaccination Status for Clinically Diagnosed Varicella Case-Subjects Aged ≥4 y in Philadelphia, Pennsylvania and 
Antelope Valley, California, 2009–2011a
Varicella Vaccination Status Overall P 2- vs 1-Dose P
Unvaccinated (n = 8), 
n (%)
1-Dose (n = 40), n (%) 2-Dose (n = 45), 
n (%)
Rash severityb .01 .81
 Mild (<50 lesions) 1 (12.5) 26 (65.0) 31 (68.9)
 Moderate or severe (50–500 lesions) 6 (75.0) 13 (32.5) 14 (31.1)
 Severe (>500 lesions) 1 (12.5) 1 (2.5) 0 (0.0)
Fever .36 .11
 Yes 2 (25.0) 16 (41.0) 11 (24.4)
 No 6 (75.0) 23 (59.0) 34 (75.6)
Most lesions are vesicular <.001 .01
 Yes 3 (60.0) 9 (23.1) 2 (4.5)
 No 2 (40.0) 30 (76.9) 42 (95.5)
Days of fever: median (IQR) 2 (0–3) 1.5 (1–2.5) 2 (1–2) .86 .57
Rash duration .01 .01
 <1 wk (<7 d) 2 (25.0) 10 (25.6) 24 (53.3)
 ≥1 wk (≥7 d) 6 (75.0) 29 (74.4) 21 (46.7)
School missed .17 .89
 ≤1 school wk (≤5 d) 2 (33.3) 3 (8.6) 3 (7.7)
 >1 school wk (>5 d) 4 (66.7) 32 (91.4) 36 (92.3)
IQR, interquartile range.
a Missing and unknown responses excluded. Valid percentages presented.
b Rash severity was defi ned as follows: <50 or the total number of spots could be counted in 30 s; 50–249 or you could place the child’s hand between the spots without touching a spot; 
250–500 or you could not place a child’s hand between the spots without touching a spot; or >500 spots or the spots were so close you could hardly see normal skin.
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between receiving 1- and 2-dose 
varicella vaccine (>5 vs ≤5 years) 
was associated with lower odds of 
developing breakthrough varicella 
(OR = 0.5, P = .03; Table 4). Subjects 
receiving dose 2 after 6 years of age 
were older than those receiving the 
second dose varicella vaccine earlier 
(12.7 vs 7.0 years, P < .001), as were 
subjects with a time interval between 
1- and 2-dose varicella vaccine >5 
years compared with those having a 
shorter interval between doses (13.0 
vs 7.4 years, P < .001).
DISCUSSION
During the first 5 years after 
implementation of 2-dose varicella 
vaccination program, we found that 
2 doses conferred significantly better 
protection against varicella disease 
from community transmission among 
school-aged children compared with 
the 1-dose regimen. By 2010, AV and 
West Philadelphia reported >60% 
2-dose varicella vaccination coverage 
among 5-year old children and 67% 
to 78% reductions in overall varicella 
incidence since 2006.15 Our study 
provides more direct evidence of 
the protective effect of a 2-dose 
regimen of varicella vaccine for 
children. Incremental effectiveness 
of the 2-dose varicella vaccination 
regimen among all subjects aged 
≥4 years was 88% to 97% against 
all forms of disease and also highly 
protective against moderate and 
severe varicella (94%). The reduction 
in community circulation of VZV 
as a result of high 2-dose coverage 
will also protect children who are 
immunocompromised and not 
eligible for varicella vaccination. 
Additional benefits of routine 
childhood varicella vaccination may 
include reduced risk of herpes zoster 
among vaccinated children.29
In 2006, concerns about the 
effectiveness of the 2-dose regimen 
were raised after a varicella 
outbreak in an Arkansas elementary 
school with 97% 1-dose varicella 
vaccination coverage and 41% 
2-dose coverage.30 Consistent 
with our findings, incremental 
effectiveness estimates from all but 
1 subsequent outbreak investigation 
and epidemiologic studies in the 
United States have been much higher 
(>90% vs 28% from the Arkansas 
outbreak).18, 20, 31, 32 Incremental 
effectiveness estimates from school 
varicella outbreak surveillance in 
Indiana and West Virginia during 
2009 to 2010 were 86% and 64%, 
respectively.18, 32 Among ~2800 
patients who were recruited into a 
prospective cohort study in 1995 at 
2 years of age and received a second 
dose through catch-up vaccination, 
no cases of breakthrough varicella 
were observed through 2009.31 
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TABLE 3  Varicella VE Against All Varicella and Moderate or Severe Varicella in Philadelphia, Pennsylvania and Antelope Valley, California, 2009–2011
Unvaccinated and 1-Dose Participants 
Regardless of Age
Participants ≥4 y Olda
Cases Controls VE (95% CI) Cases Controls VE (95% CI)
n = 79 n = 160 n = 93 n = 305
VE against any clinically diagnosed 
varicella
 Unvaccinated 17 (21.5) 12 (7.5) Reference 8 (8.6) 8 (2.6) Reference
 1-dose 62 (78.5) 148 (92.5) 75.6 (38.7–90.3) 40 (43.0) 50 (16.4) 49.1 (0–85.7)
 2-dose — — — 45 (48.4) 247 (81.0) 93.6 (75.6–98.3)
 Incremental VE (2-dose vs 1-dose) — — — — — 87.5 (74.9–93.7)
VE against moderate or severe 
clinically diagnosed varicella (≥50 
lesions)
n = 28 n = 49 — n = 35 n = 119 —
 Unvaccinated 10 (35.7) 6 (12.2) Reference 7 (20.0) 5 (4.2) Reference
 1-dose 18 (64.3) 43 (87.8) 78.1 (12.7–94.5) 14 (40.0) 20 (16.8) 64.2 (0–93.1)
 2-dose — — — 14 (40.0) 94 (79.0) 97.9 (83.0–99.7)
 Incremental VE (2-dose vs 1-dose) — — — — — 94.1 (72.4–98.8)
—, no value for category available.
a Adjusted for ethnicity given signifi cant differences between cases and controls aged ≥4 y in Philadelphia. Although day care attendance differed between cases and controls aged ≥4 y, 
only a small proportion of each group attended day care (<16%), and adding this variable to the model produced VE estimates similar to those presented.
TABLE 4  Risk Factors Associated With Breakthrough Varicella Among 2-Dose Varicella Vaccinees 
Aged ≥4 y
Cases, n (%) (n = 45) Controls, n (%) (n = 247) OR (95% CI) P
Time since 2-dose varicella vaccination
 <1 y 6 (13.3) 46 (18.6) Reference
 1–3 y 19 (42.2) 118 (47.8) 1.2 (0.5–3.3) .67
 >3 y 20 (44.4) 83 (33.6) 1.8 (0.7–4.9) .22
Age at receiving 2-dose varicella vaccine
 ≤6 y 33 (73.3) 128 (51.8) Reference
 >6 y 12 (26.7) 119 (48.2) 0.4 (0.2–0.8) .009
Time interval between receiving 1- and 2-dose varicella vaccine
 ≤5 y 34 (75.6) 144 (58.3) Reference
 >5 y 11 (24.4) 103 (41.7) 0.5 (0.2–0.9) .03
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Similarly, no 2-dose breakthrough 
varicella cases were identified in a 
community-based case–control study 
conducted by Shapiro et al20 between 
2006 and 2010.
Given the excellent protection 
provided by the 2-dose regimen in 
preventing moderate and severe 
disease, it is not surprising that the 
majority of 2-dose breakthrough 
cases (69%) had mild rashes 
with <50 lesions, and none had 
severe varicella. These findings 
were consistent with 2-dose era 
active surveillance data and other 
epidemiologic studies.15, 18, 20, 31 No 
cases in our study were hospitalized 
or fatal. Likewise, additional declines 
in varicella-related hospitalizations 
since implementation of the 2-dose 
varicella vaccination era have also 
been documented in the literature.15, 
33 Although there was no difference 
in rash severity observed between 
1- and 2-breakthrough cases, 
average illness duration for 2-dose 
breakthrough cases was slightly 
shorter than for 1-dose cases, and 
fewer 2-dose cases developed 
mostly vesicular rashes. The shorter 
duration of mild breakthrough illness 
among 2-dose recipients may add 
to the cost savings from use of this 
regimen, and infectiousness may be 
lowered, given the lower proportion 
of vesicular rashes among 2-dose 
breakthrough cases.
In our study and as reported by 
others, 1, 18, 34 breakthrough varicella 
generally has a modified appearance 
with few or no vesicular lesions, 
making it challenging to diagnose 
clinically. PCR testing of lesion 
specimens to detect VZV is highly 
sensitive and specific.35 However, 
as demonstrated during the 
investigation of a suspected varicella 
outbreak in a Texas school district 
in 2011, the utility of VZV-specific 
PCR testing can be limited when 
only macular lesions are present or 
lesion specimens are not collected 
early in the course of illness. In the 
absence of better laboratory tools, 
clinical and epidemiologic data will 
remain necessary to support the 
confirmation of varicella disease.36 In 
the Texas outbreak, the incremental 
effectiveness of 2-dose varicella 
vaccination against any form of 
clinically diagnosed varicella varied 
widely across the 2 involved schools 
(21% and 72%).36 We therefore 
chose to examine 2-dose varicella VE 
by using 2 different case definitions 
for breakthrough varicella: one based 
on clinical and epidemiologic criteria 
and the other using laboratory 
confirmation alone. Both definitions 
produced similar estimates for 
1-dose and 2-dose varicella VE when 
unvaccinated people were used as 
the comparison group. Although 
incremental effectiveness against 
laboratory-confirmed disease was 
slightly higher compared with the 
incremental effectiveness against 
clinically diagnosed disease (97% vs 
88%), both estimates demonstrate 
that the 2-dose varicella vaccine 
regimen is highly effective in 
preventing varicella due to sporadic 
VZV circulation in the community.
Data on risk factors for 2-dose 
breakthrough varicella are limited. 
Similar to Thomas et al, 18 we did not 
find a significant association between 
time since 2-dose vaccination and 
the development of breakthrough 
varicella; however, in both studies 
findings may have been affected by 
the low number of varicella cases 
among 2-dose recipients. We were 
surprised that those who were older 
at time of 2-dose varicella vaccination 
or had >5 years between dose 1 
and dose 2 had lower likelihood 
of breakthrough varicella. These 
findings may reflect a lower risk of 
VZV exposure or shorter exposure 
durations among older subjects 
in middle school and high school, 
because they are less likely to spend 
several hours with the same class of 
students throughout the school day.
Our findings are subject to the 
following limitations. Given high 
1-dose varicella vaccine coverage 
among children ≥4 years of age, 
15 very few unvaccinated subjects 
were identified, which resulted in 
wide confidence intervals for our 
estimates of varicella VE. Similarly, 
the small number of laboratory-
confirmed 2-dose breakthrough 
varicella cases limited our ability to 
identify risk factors for or describe 
the characteristics of breakthrough 
disease in 2-dose vaccinees. Lastly, 
although we used the best available 
sources of case and control subjects 
for our study, ascertainment of 
mild varicella cases was probably 
incomplete. The data source used 
to identify controls in the Antelope 
Valley area represented only 
30% of the source population, 
and the response rate among 
potential controls selected from the 
immunization registry was low in 
Philadelphia because of incomplete 
or outdated contact information. 
Despite these potential limitations, 
the distributions of demographic 
characteristics (ie, gender, race, and 
ethnicity) among control subjects 
were similar to population estimates 
for residents <18 years of age in 
each site. In AV, 2-dose varicella 
vaccination coverage was moderately 
high (84%) among kindergarten 
students during the 2009 to 
2010 school year and 98% to 99% 
among Kaiser members aged 5 to 6 
years in 2010.15 The use of Kaiser 
members only as controls probably 
did not affect 2-dose varicella 
VE but may have resulted in slightly 
higher incremental effectiveness 
estimates.
With superior protection provided 
by the 2-dose varicella vaccination 
compared with the 1-dose regimen 
as demonstrated in our study and 
others, it will be important to expand 
school immunization requirements to 
include 2-dose varicella vaccination. 
By 2012, 36 states had a 2-dose 
varicella vaccination elementary 
school entry requirement, and 2-dose 
varicella vaccine coverage among 
7
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7-year-olds in 6 sentinel sites had 
reached moderate to high levels 
(79.9%–92.0%).37 Catch-up varicella 
vaccination will be particularly 
important for 1-dose vaccinees at 
increased risk for exposure to people 
with varicella or herpes zoster (ie, 
international travelers, health care 
workers). Continued monitoring of 
2-dose varicella VE is also warranted, 
to ensure that protection is sustained 
over time.
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